Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the European Society for Medical Oncology (ESMO) Congress 2022

Analysis Evaluates Efficacy of Eribulin in Metastatic HER2-low Breast Cancer Across Three Clinical StudiesTOKYO, Sept 12, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today results from a post hoc

Related Keywords

Tokyo ,Japan ,Paris ,France General ,France , ,Eisai Co Ltd ,National Cancer Institute ,National Institutes Of Health ,Public Relations Department ,European Society For Medical Oncology ,Evaluates Efficacy ,Breast Cancer Across Three Clinical ,European Society ,Medical Oncology ,Annual Meeting ,Takashi Owa ,Chief Scientific Officer ,Senior Vice President ,National Institutes ,Stat Facts ,Female Breast ,First Targeted Therapy ,Flow Breast ,Eisai ,Presents ,Results ,Most ,Analysis ,Eribulin ,Mesylate ,Alaven ,European ,Society ,Medical ,Ncology ,Osmo ,Congress ,022 ,